Bill Few Associates Inc. Has $4.85 Million Position in Abbott Laboratories $ABT

Bill Few Associates Inc. reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 35,634 shares of the healthcare product maker’s stock after selling 392 shares during the quarter. Abbott Laboratories makes up approximately 1.4% of Bill Few Associates Inc.’s portfolio, making the stock its 20th largest position. Bill Few Associates Inc.’s holdings in Abbott Laboratories were worth $4,847,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. MOKAN Wealth Management Inc. boosted its holdings in shares of Abbott Laboratories by 11.9% during the second quarter. MOKAN Wealth Management Inc. now owns 22,007 shares of the healthcare product maker’s stock worth $2,993,000 after purchasing an additional 2,347 shares during the period. Ellis Investment Partners LLC boosted its holdings in shares of Abbott Laboratories by 2.3% during the second quarter. Ellis Investment Partners LLC now owns 4,269 shares of the healthcare product maker’s stock worth $581,000 after purchasing an additional 98 shares during the period. Genesee Capital Advisors LLC boosted its holdings in shares of Abbott Laboratories by 4.6% during the second quarter. Genesee Capital Advisors LLC now owns 8,567 shares of the healthcare product maker’s stock worth $1,165,000 after purchasing an additional 374 shares during the period. M3 Advisory Group LLC boosted its holdings in shares of Abbott Laboratories by 20.2% during the second quarter. M3 Advisory Group LLC now owns 1,858 shares of the healthcare product maker’s stock worth $253,000 after purchasing an additional 312 shares during the period. Finally, Yarger Wealth Strategies LLC boosted its holdings in shares of Abbott Laboratories by 13.4% during the second quarter. Yarger Wealth Strategies LLC now owns 3,076 shares of the healthcare product maker’s stock worth $418,000 after purchasing an additional 363 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research reports. Evercore ISI raised their price target on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Wells Fargo & Company reduced their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research note on Friday, July 18th. Mizuho lifted their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, July 16th. Finally, The Goldman Sachs Group lifted their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Abbott Laboratories Trading Down 0.8%

NYSE:ABT opened at $132.30 on Monday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The firm has a market cap of $230.26 billion, a price-to-earnings ratio of 16.58, a P/E/G ratio of 2.51 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $132.54 and its 200-day moving average is $131.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter last year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.